Company: ZLAB
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0001628280-25-018384
Chunk: 9

Company: Zai Lab Ltd
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 9
---
ung brings to the Board of Directors significant venture capital experience in the global healthcare industry as well as extensive corporate governance experience through her service on the boards of global companies listed in the United States, Hong Kong, and Shanghai.

#### Key Experience and Qualifications
• Member of the Board of Directors of Hong Kong Exchanges and Clearing Limited (June 2021-Present)

• Managing Partner at Qiming Venture Partners, where she led healthcare investments (2006-February 2025)

• Member of the Board of Directors of CanSino Biologics Inc. (HKSE) (September 2015-September 2024)

• Member of the Board of Directors of Venus Medtech (Hangzhou) Inc. (HKSE) (June 2013-January 2023)

• Member of Stanford University International Advisory Council (2024-Present)

• MBA from Stanford Graduate School of Business

#### William David Lis
Independent Director

| Age |     | Director Since |     | Board Committees                    |     | Other Public Company Boards        |
| 60  |     |           2018 |     | Nominating and Corporate Governance |     | Jasper Therapeutics, Inc. (NASDAQ) |

Mr. Lis brings to the Board of Directors over 30 years of experience in the biopharmaceutical industry, at both the executive and board level, including considerable leadership and business, financial, and product development expertise.

#### Key Experience and Qualifications
• Chief Executive Officer and member of the Board of Directors of Tr1x Biotherapeutics, Inc. (May 2023-Present)

• Various board and executive positions at Jasper Therapeutics, Inc., including Executive Chairman of the Board of Directors (March 2022-May 2023) and Chief Executive Officer and Executive Chairman of the Board of Directors (November 2019-March 2022)

<div align='center'>-4-</div>

• Member of the Board of Directors of Eidos Therapeutics, Inc. (NASDAQ) (December 2018-its acquisition by Bridge Bio Pharma, Inc. in January 2021)

• Various executive and board positions at Portola Pharmaceuticals, Inc. (later acquired by Alexion Pharmaceuticals, Inc. in 2020), including Chief Executive Officer and Member of the Board of Directors (December 2009-August 2018), Chief Operating Officer (2009), and Chief Business Officer (2008-2009)

• Various executive positions at Scios, Inc. (a Johnson &